prikaz prve stranice dokumenta The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
  Preuzmi
PDF 94.16 KB
Ostalo - Sažetak s konferencije
The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
Journal of Thoracic Oncology, 12 (2017), S1; S1283. https://doi.org/10.1016/j.jtho.2016.11.1814
Serdarevic, Marina; Kukulj, Suzana; Rebic, Ante; Drpa, Gordana; Budimir, Bernard; Popovic, Filip; Lovric, Tea; Sreter, Katherina; Samarzija, Miroslav

Institucijski repozitorij: Repozitorij Kliničkog bolničkog centra Sestre milosrdnice

Citirajte ovaj rad

Serdarevic, M., Kukulj, S., Rebic, A., Drpa, G., Budimir, B., Popovic, F. ... Samarzija, M. (2017). The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes. Journal of Thoracic Oncology, 12. (S1), S1283. doi: 10.1016/j.jtho.2016.11.1814

Serdarevic, Marina, et al. "The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes." Journal of Thoracic Oncology, vol. 12, br. S1, 2017, str. S1283. https://doi.org/10.1016/j.jtho.2016.11.1814

Serdarevic, Marina, Suzana Kukulj, Ante Rebic, Gordana Drpa, Bernard Budimir, Filip Popovic, Tea Lovric, Katherina Sreter i Miroslav Samarzija. "The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes." Journal of Thoracic Oncology 12, br. S1 (2017): S1283. https://doi.org/10.1016/j.jtho.2016.11.1814

Serdarevic, M., et al. (2017) 'The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes', Journal of Thoracic Oncology, 12(S1), str. S1283. doi: 10.1016/j.jtho.2016.11.1814

Serdarevic M, Kukulj S, Rebic A, Drpa G, Budimir B, Popovic F, i sur.. The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes. Journal of Thoracic Oncology [Internet]. 01.2017. [pristupljeno 25.11.2024.];12(S1):S1283. doi: 10.1016/j.jtho.2016.11.1814

M. Serdarevic, et al., "The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes", Journal of Thoracic Oncology, vol. 12, br. S1, str. S1283, Siječanj 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:485963. [Citirano: 25.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:485963
Podaci o radu
Naslov (engleski)The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
AutorMarina Serdarevic
AutorSuzana Kukulj
AutorAnte Rebic
MBZ: 92640
AutorGordana Drpa
AutorBernard Budimir
AutorFilip Popovic
AutorTea Lovric
AutorKatherina Sreter
AutorMiroslav Samarzija
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Lung cancer is often insidious disease. It usually produces only a few symptoms until the disease is advanced. At initial diagnosis 20% of patients have localized disease, 25% of patients have regional metastasis and 55% of patients have distant spread of disease. Metastasis is a process by which a small number of cancer cells undergo numerous alterations, which enables them to form secondary tumors at another and often multiple sites in the host. Recently, studies have suggested that cancer stem cells are the originators of metastasis. Cancer stem cells are small populations of slowly dividing, treatment – resistant, undifferentiated cancer cells that are being discovered in a different cancers. Metformin has proved to be effective in the treatment of glioblastomas and neuroblastomas, in vitro, by targeting their cancer stem cell population. Recently, studies have shown that metformin use is not associated with a decreased risk of lung cancer in patients with type 2 diabetes, but it has been suggested that metformin use is associated with improved survival among patients with stage IV NSCLC patients.
Jezikengleski
Vrsta publikacijeOstalo - Sažetak s konferencije
Status objaveObjavljen
Vrsta recenzijeNepoznato
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Thoracic Oncology
Brojčani podacivol. 12, br. S1, str. S1283
p-ISSN1556-0864
DOIhttps://doi.org/10.1016/j.jtho.2016.11.1814
URN:NBNurn:nbn:hr:220:485963
Datum objave publikacije2017-01
SkupNaziv: IASLC 17th World Conference on Lung Cancer
Lokacija: Vienna, Austrija
Organizator: International association for the study of lung cancer
Datum početka: 2016-12-04
Datum završetka: 2016-12-07
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S1556086416330556
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-10-02 10:07:45